1: Arch Ophthalmol. 2010 Mar;128(3):388. 

Ophthalmic pathology and ophthalmology--reply.

Clarkson JG.

Miller School of Medicine at the University of Miami, Clinical Research Bldg
1120 NW, 14th Street, 1560-B, Miami, FL 33136. jclarkson@miami.edu.

PMID: 20212221  [PubMed - in process]

2: Arch Ophthalmol. 2010 Mar;128(3):388. 

Rupture pressure of the healthy human eye.

Bullock JD, Warwar RE.

Department of Ophthalmology, Community Health, Mathematics and Statistics,
Wright State University, 1475 Ridge Gate Rd, Unit B, Kettering, OH 45429-1254.
johndbullock@aol.com.

PMID: 20212220  [PubMed - in process]

3: Arch Ophthalmol. 2010 Mar;128(3):387-8. 

Ophthalmic pathology and ophthalmology.

Grossniklaus HE.

L. F. Montgomery Ophthalmic Pathology Laboratory, Emory Eye Center, 1365 Clifton
Rd, BT428, Atlanta, Georgia 30322. ophtheg@emory.edu.

PMID: 20212219  [PubMed - in process]

4: Arch Ophthalmol. 2010 Mar;128(3):385-7. 

Cystic solitary fibrous tumor of the orbit.

Feuerman JM, Flint A, Elner VM.

Kellogg Eye Center, University of Michigan, 1000 Wall St, Ann Arbor, MI 48105.
velner@med.umich.edu.

PMID: 20212218  [PubMed - in process]

5: Arch Ophthalmol. 2010 Mar;128(3):384-5. 

Endogenous Streptococcus agalactiae (Group B Streptococcus) Endophthalmitis as a
Presenting Sign of Precursor T-Cell Lymphoblastic Leukemia.

Gupta SR, Agnani S, Tehrani S, Yeh S, Lauer AK, Suhler EB.

Casey Eye Institute, 3375 SW Terwilliger Blvd, Portland, OR 97239.
suhlere@ohsu.edu.

PMID: 20212217  [PubMed - in process]

6: Arch Ophthalmol. 2010 Mar;128(3):383-4. 

Socioeconomic status and choroidal melanoma in Scotland.

Lockington D, Chadha V, Russell H, Young D, Cauchi P, Kemp E.

Tennent Institute of Ophthalmology, Gartnavel General Hospital, 1053 Great
Western Rd, Glasgow G12 0YN, Scotland. davidlockington@hotmail.com.

PMID: 20212216  [PubMed - in process]

7: Arch Ophthalmol. 2010 Mar;128(3):381-3. 

Mixed tumor of the choroid.

Proia AD.

Department of Pathology, Duke University Medical Center, DUMC 3712, Durham, NC
27710. proia001@mc.duke.edu.

PMID: 20212215  [PubMed - in process]

8: Arch Ophthalmol. 2010 Mar;128(3):380-1. 

Conservative surgical treatment of medulloepithelioma of the ciliary body.

Cassoux N, Charlotte F, Sastre X, Orbach D, Lehoang P, Desjardins L.

Department of Ophthalmology, Institut Curie, 26 rue d'Ulm, 75248 Paris, CEDEX 05
France. nathalie.cassoux@psl.aphp.fr.

PMID: 20212214  [PubMed - in process]

9: Arch Ophthalmol. 2010 Mar;128(3):372-9. 

Evisceration in unsuspected intraocular tumors.

Rath S, Honavar SG, Naik MN, Gupta R, Reddy VA, Vemuganti GK.

Department of Ophthalmic Plastic Surgery, Orbit and Ocular Oncology, LV Prasad
Eye Institute, Banjara Hills, Hyderabad 500034, India. honavar@lvpei.org.

PMID: 20212213  [PubMed - in process]

10: Arch Ophthalmol. 2010 Mar;128(3):370-2. 

Bilateral superselective ophthalmic artery chemotherapy for bilateral
retinoblastoma: tandem therapy.

Abramson DH, Dunkel IJ, Brodie SE, Marr B, Gobin YP.

Ophthalmic Oncology Service, Memorial Sloan-Kettering Cancer Center, 70 E 66th
St, New York, NY 10065. abramsod@mskcc.org.

PMID: 20212212  [PubMed - in process]

11: Arch Ophthalmol. 2010 Mar;128(3):367-8. 

A transformation in ocular oncology: from megacenter to multicenter.

Harbour JW.

Ocular Oncology Service, Department of Ophthalmology and Visual Sciences and
Barnes Retina Institute, Washington University School of Medicine, St Louis, MO
63110. harbour@vision.wustl.edu.

PMID: 20212211  [PubMed - in process]

12: Arch Ophthalmol. 2010 Mar;128(3):365-6. 

Suppression and reduction of corticosteroid-induced ocular hypertension by
anecortave in sheep.

Kaufman PL.

Department of Ophthalmology and Visual Sciences, F4/334CSC-3320, University of
Wisconsin CSC, 3310 University Ave, Ste 206, Madison, WI 53792.
kaufmanp@mhub.ophth.wisc.edu.

PMID: 20212210  [PubMed - in process]

13: Arch Ophthalmol. 2010 Mar;128(3):363-4. 

Treatment of Ocular Hypertension: Hamlet's Lament Revisited.

Sommer A.

615 N Wolfe St, Ste E6527, Baltimore, MD 21205. asommer@jhsph.edu.

PMID: 20212209  [PubMed - in process]

14: Arch Ophthalmol. 2010 Mar;128(3):359-62. 

Rapid expansion of intravitreal drug injection procedures, 2000 to 2008: a
population-based analysis.

Campbell RJ, Bronskill SE, Bell CM, Paterson JM, Whitehead M, Gill SS.

Department of Ophthalmology, Queen's University and Hotel Dieu Hospital, 166
Brock St, Kingston, ON K7L 5G2, Canada. rob.campbell@queensu.ca.

OBJECTIVE: To evaluate patterns of care for age-related macular degeneration
following the introduction of vascular endothelial growth factor inhibitors.
METHODS: Using a population-based retrospective design, we studied monthly fee
claims for intravitreal injections submitted to the Ontario Health Insurance
Plan between January 1, 2000, and March 30, 2008, and linked procedures to the
physicians who performed them. This database records physician services provided
as part of universal health care insurance coverage in Ontario, Canada. This
program covers all residents of Ontario, which had an average population of 12.1
million during the study period. RESULTS: Following regulatory approval of
bevacizumab for colorectal cancer in 2005, off-label use of this drug for the
treatment of retinal disease, particularly age-related macular degeneration,
became increasingly common. The rate of intravitreal injections in Ontario
rapidly grew 8-fold, and this growth preceded the availability of ranibizumab by
more than a year. Moreover, in 2007, more than 50% of intravitreal injections in
Ontario were performed by 3% of ophthalmologists. CONCLUSIONS: The development
of vascular endothelial growth factor inhibitors has revolutionized the
treatment of age-related macular degeneration. To our knowledge, this study is
the first to quantify the dramatic uptake of these treatments at a population
level. Our findings also suggest that off-label injection of bevacizumab was
highly prevalent in Ontario. Serial intravitreal injections requiring direct
physician administration and the concentration of injection procedures in the
hands of a small number of ophthalmologists have the potential to affect
services for other vision-threatening conditions.

PMID: 20212208  [PubMed - in process]

15: Arch Ophthalmol. 2010 Mar;128(3):349-58. 

Complement, age-related macular degeneration and a vision of the future.

Gehrs KM, Jackson JR, Brown EN, Allikmets R, Hageman GS.

John A. Moran Eye Center, Department of Ophthalmology and Visual Sciences,
University of Utah, 65 Mario Capecchi Dr, Salt Lake City, UT 84132.
gregory.hageman@hsc.utah.edu.

Age-related macular degeneration (AMD) is one of the most well-characterized
late-onset, complex trait diseases. Remarkable advances in our understanding of
the genetic and biological foundations of this disease were derived from a
recent convergence of scientific and clinical data. Importantly, the more recent
identification of AMD-associated variations in a number of complement pathway
genes has provided strong support for earlier, paradigm-shifting studies that
suggested that aberrant function of the complement system plays a key role in
disease etiology. Collectively, this wealth of information has provided an
impetus for the development of powerful tools to accurately diagnose disease
risk and progression and complement-based therapeutics that will ultimately
delay or prevent AMD. Indeed, we are poised to witness a new era of a
personalized approach toward the assessment, management, and treatment of this
debilitating, chronic disease.

PMID: 20212207  [PubMed - in process]

16: Arch Ophthalmol. 2010 Mar;128(3):344-8. 

Helicoid Subretinal Fibrosis Associated With a Novel Recessive NR2E3 Mutation
p.S44X.

Khan AO, Aldahmesh MA, Al-Harthi E, Alkuraya FS.

Division of Pediatric Ophthalmology, King Khaled Eye Specialist Hospital, PO Box
7191, Riyadh 11462, Saudi Arabia. arif.khan@mssm.edu.

OBJECTIVES: To describe a unique pattern of helicoid subretinal fibrosis
associated with a novel recessive NR2E3 mutation and to highlight how
examination of the proband's affected relative allowed appropriate genetic
testing. DESIGN: Interventional family study (ophthalmic examination and
candidate gene testing). RESULTS: The proband (mother), who complained of poor
vision since early childhood, had bilateral helicoid subretinal fibrosis mostly
involving the macula. Two children were symptomatic; one had ophthalmic findings
similar to her mother while the second had macular retinoschisis, retinal
pigment epithelium changes, and refractive accommodative esotropia. The father
and third child were asymptomatic and had unremarkable ophthalmic examination
findings. Based on the findings in the second symptomatic child, NR2E3 analysis
was performed, which revealed homozygosity for a novel mutation, p.S44X, in all
3 affected individuals and heterozygosity for the mutation in both asymptomatic
individuals. CONCLUSION: Helicoid subretinal fibrosis is another potential
phenotypic manifestation of recessive NR2E3 mutation. Clinical Relevance
Examination of affected relatives can be helpful in guiding molecular genetic
testing for hereditary eye disease when the proband's diagnosis is unclear.

PMID: 20212206  [PubMed - in process]

17: Arch Ophthalmol. 2010 Mar;128(3):338-43. 

Suppression of corticosteroid-induced ocular hypertension in sheep by
anecortave.

Candia OA, Gerometta R, Millar JC, Podos SM.

Mount Sinai School of Medicine, 100th Street and Fifth Avenue, New York, NY
10029. oscar.candia@mssm.edu.

OBJECTIVE: To confirm the ocular hypotensive effects of anecortave acetate on an
ovine model for steroid-induced ocular hypertension. Eyes of normal sheep
exhibit a robust steroid-induced ocular hypertensive response. Recent
observations in an uncontrolled, interventional case series indicated that
anecortave elicited hypotensive effects when administered as a sub-Tenon depot
in the eyes of a small sample of patients with glaucoma. METHODS: Intraocular
pressure (IOP) was monitored by Perkins applanation tonometry in 16 normal sheep
receiving topically administered prednisolone acetate, 0.5%, in both eyes, 3
times daily, a protocol that doubled IOP within 12 days. Half of the sheep had
received a unilateral sub-Tenon injection of anecortave in 1 eye prior to the
initiation of the bilateral prednisolone instillations, while the 8 remaining
sheep received the unilateral anecortave sub-Tenon depot after the IOP was
maximally elevated by the prednisolone instillations. RESULTS: In these 2 sets
of experiments, the presence of the anecortave depot suppressed the
steroid-induced IOP elevation and reverted the elevated IOP to baseline levels.
Measurements of aqueous outflow facility indicated that eyes treated with
prednisolone plus anecortave exhibited a 5.8-fold higher outflow facility than
the fellow eyes solely exposed to prednisolone, indicating that anecortave
prevented the increase in outflow resistance produced by the corticosteroid.
CONCLUSION: Elucidation of the mechanisms of action of anecortave in animal
models may prove relevant to the design of novel interventions for the
management of primary open-angle glaucoma.

PMID: 20212205  [PubMed - in process]

18: Arch Ophthalmol. 2010 Mar;128(3):330-337. 

Visual Field Profile of Optic Neuritis: A Final Follow-up Report From the Optic
Neuritis Treatment Trial From Baseline Through 15 Years.

Keltner JL, Johnson CA, Cello KE, Dontchev M, Gal RL, Beck RW; for the Optic
Neuritis Study Group.

Department of Ophthalmology and Vision Science, University of California, Davis,
4860 Y St, Ste 2400, Sacramento, CA 95817. jlkeltner@ucdavis.edu.

OBJECTIVE: To evaluate visual field abnormalities after an episode of optic
neuritis among participants in the Optic Neuritis Treatment Trial. METHODS:
Three readers independently evaluated 10 443 visual fields from 454 patients and
classified visual field abnormalities into 21 different monocular categories
representing 3 general types of visual loss: diffuse, localized, and
artifactual. Classification frequency was determined and reader agreement was
evaluated. The association of visual field abnormality classifications with mean
deviation, pattern standard deviation, visual acuity, and foveal threshold was
assessed. RESULTS: At baseline, diffuse loss accounted for 66.2% of the
abnormalities in the affected eyes but only 6.2% of the abnormalities in the
fellow eyes. During years 1 through 15, the affected and fellow eyes exhibited
predominantly localized loss in the nerve fiber bundle region (partial arcuate,
paracentral, and arcuate defects). At year 1, 35.7% of the abnormalities in the
affected eyes and 34.4% in the fellow eyes consisted of localized defects. At
year 15, 39.5% of abnormalities in the affected eyes and 26.3% in the fellow
eyes consisted of localized defects. Foveal threshold was highly correlated with
visual acuity and contrast sensitivity in the affected eye at baseline (-0.82 vs
0.79, respectively), 6 months (-0.84 vs 0.81), and 1 year (-0.84 vs 0.79).
CONCLUSIONS: Diffuse and central loss were more predominant in the affected eye
at baseline, and nerve fiber bundle defects (partial arcuate, paracentral, and
arcuate) were the most predominant localized abnormalities in both the affected
and fellow eyes during the study.

PMID: 20212204  [PubMed - as supplied by publisher]

19: Arch Ophthalmol. 2010 Mar;128(3):324-9. 

Incidence of pediatric horner syndrome and the risk of neuroblastoma: a
population-based study.

Smith SJ, Diehl N, Leavitt JA, Mohney BG.

Department of Ophthalmology, Mayo Clinic, 200 First St SW, Rochester, MN 55905.
mohney@mayo.edu.

OBJECTIVE: To describe the incidence of pediatric Horner syndrome and the risk
of occult malignancy in a population-based cohort. METHODS: The medical records
of all pediatric patients (aged <19 years) residing in Olmsted County,
Minnesota, who received diagnoses of Horner syndrome from January 1, 1969,
through December 31, 2008, were retrospectively reviewed. RESULTS: Horner
syndrome was diagnosed in 20 pediatric patients during the 40-year period,
yielding an age- and sex-adjusted incidence of 1.42 per 100 000 patients younger
than 19 years of age (95% confidence interval [CI], 0.80-2.04). Eleven of the 20
patients (55%) had a congenital onset, for a birth prevalence of 1 in 6250 (95%
CI, 3333-10 000), while the remaining 9 (45%) had acquired syndromes. Seven of
the 11 (63.6%) patients with congenital cases had a history of birth trauma,
while the remaining 4 (36.4%) had no identifiable cause. Six of the 9 (66%)
acquired cases occurred following surgery or trauma, while the remaining 3 (33%)
had no known etiology. None of the 20 patients (95% CI, 0.0%-16.8%) were found
to have a neuroblastoma or other malignancy during a mean follow-up of 56.5
months (range, 0-256.9 months). CONCLUSIONS: The incidence of pediatric Horner
syndrome in this population was 1.42 per 100 000 patients younger than 19 years,
with a birth prevalence of 1 in 6250 for those with a congenital onset. Birth,
surgical, or other trauma occurred in 13 (65%) of the patients, while none were
found to have an underlying mass lesion, suggesting a need for reappraising
current recommendations for extensive evaluations in these patients.

PMID: 20212203  [PubMed - in process]

20: Arch Ophthalmol. 2010 Mar;128(3):319-23. 

Hepatic abnormalities identified on abdominal computed tomography at diagnosis
of uveal melanoma.

Feinstein EG, Marr BP, Winston CB, Abramson DH.

Ophthalmic Oncology Service, Memorial Sloan-Kettering Cancer Center, 70 E 66th
St, New York, NY 10065. abramsod@mskcc.org.

OBJECTIVE: To determine the prevalence of hepatic abnormalities identified
during abdominal computed tomography (CT) performed within 1 month of the
diagnosis of primary uveal melanoma. METHODS: Retrospective review of CT reports
generated within 1 month following diagnosis of uveal melanoma in 91 patients at
Memorial Sloan-Kettering Cancer Center, New York, New York, from 2004 to 2009.
RESULTS: Of 198 patients reviewed, 91 (46%) had a CT scan within 1 month of
uveal melanoma diagnosis; 1 or more hepatic abnormalities were identified in 50
of these patients (55%). Abnormalities included 38 focal (13 solitary, 25
multiple) and 15 diffuse (11 partial, 4 complete) lesions. Six patients had
hepatic lesions suspected to be metastatic melanoma, but this was confirmed in
only 3. Lesions suspected to be metastases were more likely multiple than
solitary (P = .03). Thirty-nine patients had other lesions, most commonly
lesions that were too small to be characterized, a fatty liver, and hepatic
cysts. Lesions in 5 of 50 patients with abnormalities could not be classified.
Neither the protocol (triphasic vs nontriphasic) nor the center where the scan
was performed (Sloan-Kettering vs other) was significantly related to the
likelihood of identifying hepatic abnormalities in a given patient (P = .46 and
P = .1, respectively). CONCLUSION: Although hepatic abnormalities were
frequently identified in patients who underwent CT within 1 month of uveal
melanoma diagnosis, metastatic disease was confirmed only in the setting of
multiple lesions in only a minority of patients.

PMID: 20212202  [PubMed - in process]

21: Arch Ophthalmol. 2010 Mar;128(3):312-318. 

Lack of Association Between Thiazolidinediones and Macular Edema in Type 2
Diabetes: The ACCORD Eye Substudy.

Ambrosius WT, Danis RP, Goff DC Jr, Greven CM, Gerstein HC, Cohen RM, Riddle MC,
Miller ME, Buse JB, Bonds DE, Peterson KA, Rosenberg YD, Perdue LH, Esser BA,
Seaquist LA, Felicetta JV, Chew EY; for the ACCORD Study Group.

Department of Biostatistical Sciences, Division of Public Health Sciences, Wake
Forest University Health Sciences, Medical Center Boulevard, Winston-Salem, NC
27157. wambrosi@wfubmc.edu.

OBJECTIVE: To assess the cross-sectional association of thiazolidinediones with
diabetic macular edema (DME). METHODS: The cross-sectional association of DME
and visual acuity with thiazolidinediones was examined by means of baseline
fundus photographs and visual acuity measurements from the Action to Control
Cardiovascular Risk in Diabetes (ACCORD) trial. Visual acuity was assessed in
9690 participants in the ACCORD trial, and 3473 of these participants had fundus
photographs that were centrally read in a standardized fashion by masked graders
to assess DME and retinopathy from October 23, 2003, to March 10, 2006. RESULTS:
Among the subsample, 695 (20.0%) people had used thiazolidinediones, whereas 217
(6.2%) people had DME. Thiazolidinedione use was not associated with DME in
unadjusted (odds ratio [OR], 1.01; 95% confidence interval [CI], 0.71-1.44; P =
.95) and adjusted (OR, 0.97; 95% CI, 0.67-1.40; P = .86) analyses. Significant
associations with DME were found for retinopathy severity (P < .001) and age
(OR, 0.97; 95% CI, 0.952-0.997; P = .03) but not for hemoglobin A(1c) (P = .06),
duration of diabetes (P = .65), sex (P = .72), and ethnicity (P = .20).
Thiazolidinedione use was associated with slightly greater visual acuity (0.79
letter; 95% CI, 0.20-1.38; P = .009) of uncertain clinical significance.
CONCLUSIONS: In a cross-sectional analysis of data from the largest study to
date, no association was observed between thiazolidinedione exposure and DME in
patients with type 2 diabetes; however, we cannot exclude a modest protective or
harmful association. Trial Registration clinicaltrials.gov Identifier:
NCT00542178.

PMID: 20212201  [PubMed - as supplied by publisher]

22: Arch Ophthalmol. 2010 Mar;128(3):303-11. 

Phacoemulsification vs Phacotrabeculectomy in Chronic Angle-closure Glaucoma
With Cataract Complications.

Tham CC, Kwong YY, Leung DY, Lam SW, Li FC, Chiu TY, Chan JC, Lam DS, Lai JS.

Department of Ophthalmology and Visual Sciences, The Chinese University of Hong
Kong, Hong Kong Eye Hospital, 147K Argyle St, Kowloon, Hong Kong, China.
clemtham@hkstar.com.

OBJECTIVE: To compare the complications of phacoemulsification alone vs combined
phacotrabeculectomy in chronic angle-closure glaucoma (CACG) with coexisting
cataract. METHODS: Patients with CACG with coexisting cataract recruited into 2
randomized controlled trials comparing phacoemulsification alone vs combined
phacotrabeculectomy were pooled for analysis. The first trial recruited patients
with medically controlled intraocular pressure, while the second trial recruited
patients with medically uncontrolled intraocular pressure. The 2 trials had
otherwise identical study designs. All patients were reviewed every 3 months for
2 years after surgery. The main outcome measure was the surgical complications
of phacoemulsification alone vs combined phacotrabeculectomy in CACG eyes with
cataract. RESULTS: One hundred twenty-three CACG eyes with cataract from 123
patients were included. Sixty-two CACG eyes were randomized to receive
phacoemulsification alone, and 61 eyes had combined phacotrabeculectomy. In the
phacoemulsification group, 5 of the 62 CACG eyes (8.1%) had a total of 5
surgical complications. In the combined phacotrabeculectomy group, 16 of the 61
CACG eyes (26.2%) had a total of 19 surgical complications. The difference in
the proportion of eyes with 1 or more surgical complications between the 2
treatment groups was statistically significant (P = .007, Pearson chi(2) test).
There was no statistically significant difference in final visual acuity or
glaucomatous progression during the 24-month follow-up. CONCLUSIONS: Combined
phacotrabeculectomy resulted in significantly more surgical complications than
phacoemulsification alone in CACG eyes with coexisting cataract. There was no
difference in visual acuity or disease progression between the 2 treatment
groups.

PMID: 20212200  [PubMed - in process]

23: Arch Ophthalmol. 2010 Mar;128(3):302. 

Dr Thompson's Eye Water.

[No authors listed]

PMID: 20212199  [PubMed - in process]

24: Arch Ophthalmol. 2010 Mar;128(3):297-302. 

Effectiveness of telescopic magnification in the treatment of amblyopia: a pilot
study.

Wu J, Nazemi F, Schofield J, Mirabella G, Wong AM.

FRCSC, Department of Ophthalmology and Vision Sciences, The Hospital for Sick
Children, 555 University Ave, Toronto, ON M5G 1X8, Canada.
agnes.wong@utoronto.ca.

OBJECTIVE: To compare the effectiveness of patching plus telescopic
magnification vs patching alone in treating refractory amblyopia. METHODS:
Children aged 4 to 17 years who failed previous amblyopia treatment were
recruited into this prospective study. Subjects were randomly assigned to either
30 minutes per day of patching of the fellow eye only (n = 7) or 30 minutes per
day of patching of the fellow eye plus concurrent use of a telescope in the
amblyopic eye (n = 8). Main Outcome Measure Best-corrected logMAR visual acuity
score of the amblyopic eye after 17 weeks of treatment. RESULTS: Both treatment
groups demonstrated significant improvement in visual acuity in the amblyopic
eye after 17 weeks (P = .001). Improvements in the patching-only group were
slightly greater over the course of treatment, but this difference was not
statistically significant (P = .06). At 17 weeks, mean visual acuity improvement
from baseline was 0.14 logMAR (SD, 0.13 logMAR) in the patching-only group and
0.06 logMAR (SD, 0.17 logMAR) in the patching plus telescope group (P = .11).
The 17-week visual acuity was at least 0.2 logMAR and/or improved from baseline
by at least 0.2 logMAR in 2 patients in the patching-only group and none in the
patching plus telescope group (P = .08). CONCLUSION: Treatment of refractory
amblyopia in children using telescopic magnification did not appear to confer
any additional benefits over patching alone. Application to Clinical Practice
Occlusion and penalization remain the standard of care for patients with
amblyopia and should remain the benchmark against which other treatments are
compared in clinical trials for amblyopia therapy. Trial Registration
clinicaltrials.gov Identifier: NCT00970554.

PMID: 20212198  [PubMed - in process]

25: Arch Ophthalmol. 2010 Mar;128(3):289-296. 

Randomized Controlled Trial of an Intravitreous Dexamethasone Drug Delivery
System in Patients With Diabetic Macular Edema.

Haller JA, Kuppermann BD, Blumenkranz MS, Williams GA, Weinberg DV, Chou C,
Whitcup SM; for the Dexamethasone DDS Phase II Study Group.

Wills Eye Institute, 840 Walnut St, Ste 1510, Philadelphia, PA 19107.
jhaller@willseye.org.

OBJECTIVE: To evaluate the safety and efficacy of a dexamethasone intravitreous
drug delivery system (DDS) in eyes with diabetic macular edema (DME). METHODS:
Patients with persistent macular edema (>/=90 days' duration) were randomized to
treatment with 700 mug or 350 mug of dexamethasone DDS or observation. One eye
from each patient was designated as the study eye. The analysis is of the eyes
in this study with DME (n = 171). MAIN OUTCOME MEASURES: The primary outcome
measure was the proportion of eyes that achieved an improvement in
best-corrected visual acuity (BCVA) of 10 letters or more from baseline at day
90. Other outcome measures included fluorescein leakage, central retinal
thickness, and safety parameters. RESULTS: At day 90, a BCVA improvement of 10
letters or more was seen in more eyes in the 700-mug group (33.3%) and 350-mug
group (21.1%) than the observation group (12.3%; P = .007 vs 700-mug group). At
day 180, a BCVA improvement of 10 letters or more was seen in 30% of eyes in the
700-mug group, 19% in the 350-mug group, and 23% in the observation group (P >/=
.4 for treated vs observed eyes). There were also significantly greater
improvements in central retinal thickness and fluorescein leakage in treated
eyes than observed eyes (P = .03; day 90). Dexamethasone DDS was well tolerated.
CONCLUSIONS: In eyes with persistent DME, treatment with 700 mug of intravitreal
dexamethasone DDS is well tolerated and produces significant improvements in
BCVA, central retinal thickness, and fluorescein leakage compared with
observation (statistically significant at day 90). Application to Clinical
Practice Dexamethasone DDS, 700 mug, may have potential as a treatment for
persistent DME. Trial Registration clinicaltrials.gov Identifier: NCT00035906.

PMID: 20212197  [PubMed - as supplied by publisher]

26: Arch Ophthalmol. 2010 Mar;128(3):276-287. 

Delaying Treatment of Ocular Hypertension: The Ocular Hypertension Treatment
Study.

Kass MA, Gordon MO, Gao F, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JK,
Miller JP, Parrish RK, Wilson MR; for the Ocular Hypertension Treatment Study
Group.

Ocular Hypertension Treatment Study Coordinating Center, Department of
Ophthalmology and Visual Sciences, Washington University School of Medicine, Box
8203, 660 S Euclid Ave, St Louis, MO 63110. mae@vrcc.wustl.edu.

OBJECTIVE: To compare the safety and efficacy of earlier vs later treatment in
preventing primary open-angle glaucoma (POAG) in individuals with ocular
hypertension. METHODS: One thousand six hundred thirty-six individuals with
intraocular pressure (IOP) from 24 to 32 mm Hg in 1 eye and 21 to 32 mm Hg in
the fellow eye were randomized to observation or to topical ocular hypotensive
medication. Median time of treatment in the medication group was 13.0 years.
After a median of 7.5 years without treatment, the observation group received
medication for a median of 5.5 years. To determine if there is a penalty for
delaying treatment, we compared the cumulative proportions of participants who
developed POAG at a median follow-up of 13 years in the original observation
group and in the original medication group. MAIN OUTCOME MEASURES: Cumulative
proportion of participants who developed POAG. RESULTS: The cumulative
proportion of participants in the original observation group who developed POAG
at 13 years was 0.22 (95% confidence interval [CI], 0.19-0.25), vs 0.16 (95% CI,
0.13-0.19) in the original medication group (P = .009). Among participants at
the highest third of baseline risk of developing POAG, the cumulative proportion
who developed POAG was 0.40 (95% CI, 0.33-0.46) in the original observation
group and 0.28 (95% CI, 0.22-0.34) in the original medication group. There was
little evidence of increased adverse events associated with medication.
Application to Clinical Practice Absolute reduction was greatest among
participants at the highest baseline risk of developing POAG. Individuals at
high risk of developing POAG may benefit from more frequent examinations and
early preventive treatment. Trial Registration clinicaltrials.gov Identifier:
NCT00000125.

PMID: 20212196  [PubMed - as supplied by publisher]

27: Arch Ophthalmol. 2010 Mar 8; [Epub ahead of print] 

Intravitreous Dexamethasone Effects on Different Patterns of Diabetic Macular
Edema.

Kuppermann BD, Chou C, Weinberg DV, Whitcup SM, Haller JA, Blumenkranz MS; for
the Dexamethasone DDS Phase II Study Group.

PMID: 20212194  [PubMed - as supplied by publisher]

28: Arch Ophthalmol. 2010 Feb;128(2):262; author reply 262. 

Diabetic macular edema following panretinal photocoagulation.

Falavarjani KG, Modarres M, Nazari H, Naseripour M, Parvaresh MM.

Publication Types:
    Comment
    Letter

PMID: 20142560  [PubMed - indexed for MEDLINE]

29: Arch Ophthalmol. 2010 Feb;128(2):259-62. 

Severe retinal vascular infarction after photodynamic therapy with verteporfin
using the standard protocol.

Koizumi H, Hatanaka H.

Publication Types:
    Case Reports
    Letter

PMID: 20142558  [PubMed - indexed for MEDLINE]

30: Arch Ophthalmol. 2010 Feb;128(2):258-9. 

Ocular involvement by epstein-barr virus-positive diffuse large B-cell lymphoma
of the elderly: a new disease entity in the world health organization
classification.

Tsuji H, Tamura M, Yokoyama M, Takeuchi K, Mimura T.

Publication Types:
    Case Reports
    Letter
    Research Support, Non-U.S. Gov't

PMID: 20142557  [PubMed - indexed for MEDLINE]